10-Q Filing

GUARDANT HEALTH, INC. CIK: 1576280 Q3 2021

Filing Information

Form Type	10-Q
Accession Number	`0001576280-21-000105`
Period End Date	20210930
Filing Date	20211104
Fiscal Year	2021
Fiscal Period	Q3
XBRL Instance	gh-20210930_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 75 Income Statement 92 Cash Flow Statement 97 Stockholders Equity 46 Comprehensive Income 28

Balance Sheet 75 line items

Line Item	Tag	Value	Unit	Period
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$142.94M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$832.37M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$832.98M	USD	Point-in-time
Short-term marketable securities	`MarketableSecuritiesCurrent`	$653.60M	USD	Point-in-time
Short-term marketable securities	`MarketableSecuritiesCurrent`	$961.90M	USD	Point-in-time
Accounts receivable, net	`AccountsReceivableNetCurrent`	$60.74M	USD	Point-in-time
Accounts receivable, net	`AccountsReceivableNetCurrent`	$53.30M	USD	Point-in-time
Inventory	`InventoryNet`	$24.74M	USD	Point-in-time
Common stock, par value (in usd per share)	`CommonStockParOrStatedValuePerShare`	-	USD	Point-in-time
Common stock, par value (in usd per share)	`CommonStockParOrStatedValuePerShare`	-	USD	Point-in-time
Inventory	`InventoryNet`	$22.72M	USD	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	350.00M	shares	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	350.00M	shares	Point-in-time
Prepaid expenses and other current assets, net	`PrepaidExpenseAndOtherAssetsCurrent`	$17.47M	USD	Point-in-time
Prepaid expenses and other current assets, net	`PrepaidExpenseAndOtherAssetsCurrent`	$21.96M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$1.89B	USD	Point-in-time
Common stock, shares outstanding (in shares)	`CommonStockSharesOutstanding`	101.62M	shares	Point-in-time
Common stock, shares outstanding (in shares)	`CommonStockSharesOutstanding`	100.21M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$1.59B	USD	Point-in-time
Long-term marketable securities	`MarketableSecuritiesNoncurrent`	$246.60M	USD	Point-in-time
Long-term marketable securities	`MarketableSecuritiesNoncurrent`	$250.23M	USD	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	100.21M	shares	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	101.62M	shares	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$62.78M	USD	Point-in-time
Assets	`Assets`	$2.23B	USD	Point-in-time
Assets	`Assets`	$2.27B	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$106.16M	USD	Point-in-time
Right-of-use assets	`OperatingLeaseRightOfUseAsset`	$37.34M	USD	Point-in-time
Liabilities	`Liabilities`	$916.19M	USD	Point-in-time
Liabilities	`Liabilities`	$1.46B	USD	Point-in-time
Right-of-use assets	`OperatingLeaseRightOfUseAsset`	$196.44M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$16.16M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$14.70M	USD	Point-in-time
Goodwill	`Goodwill`	$3.29M	USD	Point-in-time
Goodwill	`Goodwill`	$3.29M	USD	Point-in-time
Other assets, net	`OtherAssetsNoncurrent`	$61.32M	USD	Point-in-time
Other assets, net	`OtherAssetsNoncurrent`	$17.25M	USD	Point-in-time
Total Assets	`Assets`	$2.23B	USD	Point-in-time
Total Assets	`Assets`	$2.27B	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$15.67M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$7.34M	USD	Point-in-time
Accrued compensation	`DeferredCompensationLiabilityCurrent`	$38.84M	USD	Point-in-time
Accrued compensation	`DeferredCompensationLiabilityCurrent`	$28.28M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$22.64M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$40.48M	USD	Point-in-time
Deferred revenue	`ContractWithCustomerLiabilityCurrent`	$7.32M	USD	Point-in-time
Deferred revenue	`ContractWithCustomerLiabilityCurrent`	$8.55M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$102.30M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$66.81M	USD	Point-in-time
Convertible senior notes, net	`ConvertibleDebtNoncurrent`	$1.13B	USD	Point-in-time
Convertible senior notes, net	`ConvertibleDebtNoncurrent`	$806.29M	USD	Point-in-time
Long-term operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$41.56M	USD	Point-in-time
Long-term operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$216.81M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$3.42M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$1.52M	USD	Point-in-time
Total Liabilities	`Liabilities`	$916.19M	USD	Point-in-time
Total Liabilities	`Liabilities`	$1.46B	USD	Point-in-time
Redeemable noncontrolling interest	`RedeemableNoncontrollingInterestEquityCarryingAmount`	$57.10M	USD	Point-in-time
Redeemable noncontrolling interest	`RedeemableNoncontrollingInterestEquityCarryingAmount`	$59.40M	USD	Point-in-time
Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of September 30, 2021, and December 31, 2020; 101,623,257 and 100,213,985 shares issued and outstanding as of September 30, 2021, and December 31, 2020, respectively	`CommonStockValueOutstanding`	$1.00K	USD	Point-in-time
Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of September 30, 2021, and December 31, 2020; 101,623,257 and 100,213,985 shares issued and outstanding as of September 30, 2021, and December 31, 2020, respectively	`CommonStockValueOutstanding`	$1.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$1.90B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$1.63B	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$2.70M	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-593.00K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-606.59M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-916.91M	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$1.30B	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$1.11B	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$798.39M	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$1.09B	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$788.07M	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$709.42M	USD	Point-in-time
Total Liabilities, Redeemable Noncontrolling Interest and Stockholders Equity	`LiabilitiesAndStockholdersEquity`	$2.27B	USD	Point-in-time
Total Liabilities, Redeemable Noncontrolling Interest and Stockholders Equity	`LiabilitiesAndStockholdersEquity`	$2.23B	USD	Point-in-time

Income Statement 92 line items

Line Item	Tag	Value	Unit	Period
Precision oncology testing	`RevenuefromPrecisionOncologyTesting`	$60.38M	USD	1 Quarter
Precision oncology testing	`RevenuefromPrecisionOncologyTesting`	$171.62M	USD	3 Qtrs
Precision oncology testing	`RevenuefromPrecisionOncologyTesting`	$79.27M	USD	1 Quarter
Precision oncology testing	`RevenuefromPrecisionOncologyTesting`	$215.60M	USD	3 Qtrs
Development services and other	`RevenuefromDevelopmentServices`	$15.51M	USD	1 Quarter
Development services and other	`RevenuefromDevelopmentServices`	$36.79M	USD	3 Qtrs
Development services and other	`RevenuefromDevelopmentServices`	$49.94M	USD	3 Qtrs
Development services and other	`RevenuefromDevelopmentServices`	$14.19M	USD	1 Quarter
Total revenue	`Revenues`	$208.41M	USD	3 Qtrs
Total revenue	`Revenues`	$74.57M	USD	1 Quarter
Total revenue	`Revenues`	$94.78M	USD	1 Quarter
Total revenue	`Revenues`	$265.55M	USD	3 Qtrs
Cost of precision oncology testing	`CostsofPrecisionOncologyTesting`	$29.66M	USD	1 Quarter
Cost of precision oncology testing	`CostsofPrecisionOncologyTesting`	$16.70M	USD	1 Quarter
Cost of precision oncology testing	`CostsofPrecisionOncologyTesting`	$78.14M	USD	3 Qtrs
Cost of precision oncology testing	`CostsofPrecisionOncologyTesting`	$52.70M	USD	3 Qtrs
Cost of development services and other	`CostofDevelopmentServices`	$11.43M	USD	3 Qtrs
Cost of development services and other	`CostofDevelopmentServices`	$1.15M	USD	1 Quarter
Cost of development services and other	`CostofDevelopmentServices`	$4.49M	USD	1 Quarter
Cost of development services and other	`CostofDevelopmentServices`	$11.35M	USD	3 Qtrs
Research and development expense	`ResearchAndDevelopmentExpense`	$70.97M	USD	1 Quarter
Research and development expense	`ResearchAndDevelopmentExpense`	$109.58M	USD	3 Qtrs
Research and development expense	`ResearchAndDevelopmentExpense`	$190.20M	USD	3 Qtrs
Research and development expense	`ResearchAndDevelopmentExpense`	$36.24M	USD	1 Quarter
Sales and marketing expense	`SellingAndMarketingExpense`	$50.23M	USD	1 Quarter
Sales and marketing expense	`SellingAndMarketingExpense`	$25.09M	USD	1 Quarter
Sales and marketing expense	`SellingAndMarketingExpense`	$132.28M	USD	3 Qtrs
Sales and marketing expense	`SellingAndMarketingExpense`	$75.22M	USD	3 Qtrs
General and administrative expense	`GeneralAndAdministrativeExpense`	$66.29M	USD	1 Quarter
General and administrative expense	`GeneralAndAdministrativeExpense`	$50.05M	USD	1 Quarter
General and administrative expense	`GeneralAndAdministrativeExpense`	$166.37M	USD	3 Qtrs
General and administrative expense	`GeneralAndAdministrativeExpense`	$123.27M	USD	3 Qtrs
Total costs and operating expenses	`CostsAndExpenses`	$578.34M	USD	3 Qtrs
Total costs and operating expenses	`CostsAndExpenses`	$202.07M	USD	1 Quarter
Total costs and operating expenses	`CostsAndExpenses`	$148.82M	USD	1 Quarter
Total costs and operating expenses	`CostsAndExpenses`	$372.20M	USD	3 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-312.79M	USD	3 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-107.29M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-163.78M	USD	3 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-74.25M	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$689.00K	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$2.31M	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$3.28M	USD	3 Qtrs
Interest income	`InvestmentIncomeInterest`	$8.27M	USD	3 Qtrs
Interest expense	`InterestExpense`	$1.93M	USD	3 Qtrs
Interest expense	`InterestExpense`	$8.00K	USD	1 Quarter
Interest expense	`InterestExpense`	$644.00K	USD	1 Quarter
Interest expense	`InterestExpense`	$30.00K	USD	3 Qtrs
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$2.42M	USD	3 Qtrs
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$-720.00K	USD	3 Qtrs
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$345.00K	USD	1 Quarter
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$-187.00K	USD	1 Quarter
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-312.17M	USD	3 Qtrs
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-153.12M	USD	3 Qtrs
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-107.43M	USD	1 Quarter
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-71.60M	USD	1 Quarter
Provision for income taxes	`IncomeTaxExpenseBenefit`	$116.00K	USD	3 Qtrs
Provision for income taxes	`IncomeTaxExpenseBenefit`	$96.00K	USD	1 Quarter
Provision for income taxes	`IncomeTaxExpenseBenefit`	$68.00K	USD	1 Quarter
Provision for income taxes	`IncomeTaxExpenseBenefit`	$289.00K	USD	3 Qtrs
Net loss	`ProfitLoss`	$-312.46M	USD	3 Qtrs
Net loss	`ProfitLoss`	$-71.67M	USD	1 Quarter
Net loss	`ProfitLoss`	$-153.24M	USD	3 Qtrs
Net loss	`ProfitLoss`	$-107.53M	USD	1 Quarter
Adjustment of redeemable noncontrolling interest	`NetIncomeLossAttributableToRedeemableNoncontrollingInterest`	$6.80M	USD	3 Qtrs
Adjustment of redeemable noncontrolling interest	`NetIncomeLossAttributableToRedeemableNoncontrollingInterest`	$2.30M	USD	3 Qtrs
Adjustment of redeemable noncontrolling interest	`NetIncomeLossAttributableToRedeemableNoncontrollingInterest`	-	USD	1 Quarter
Adjustment of redeemable noncontrolling interest	`NetIncomeLossAttributableToRedeemableNoncontrollingInterest`	$6.00M	USD	1 Quarter
Net loss attributable to Guardant Health, Inc. common stockholders	`NetIncomeLossAvailableToCommonStockholdersDiluted`	$-107.53M	USD	1 Quarter
Net loss attributable to Guardant Health, Inc. common stockholders	`NetIncomeLossAvailableToCommonStockholdersDiluted`	$-77.67M	USD	1 Quarter
Net loss attributable to Guardant Health, Inc. common stockholders	`NetIncomeLossAvailableToCommonStockholdersDiluted`	$-160.04M	USD	3 Qtrs
Net loss attributable to Guardant Health, Inc. common stockholders	`NetIncomeLossAvailableToCommonStockholdersDiluted`	$-314.76M	USD	3 Qtrs
Net loss attributable to Guardant Health, Inc. common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-160.04M	USD	3 Qtrs
Net loss attributable to Guardant Health, Inc. common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-314.76M	USD	3 Qtrs
Net loss attributable to Guardant Health, Inc. common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-107.53M	USD	1 Quarter
Net loss attributable to Guardant Health, Inc. common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-77.67M	USD	1 Quarter
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in usd per share)	`EarningsPerShareBasic`	$-3.11	USD	3 Qtrs
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in usd per share)	`EarningsPerShareBasic`	$-1.66	USD	3 Qtrs
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in usd per share)	`EarningsPerShareBasic`	$-1.06	USD	1 Quarter
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in usd per share)	`EarningsPerShareBasic`	$-0.78	USD	1 Quarter
Net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in usd per share)	`EarningsPerShareDiluted`	$-1.06	USD	1 Quarter
Net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in usd per share)	`EarningsPerShareDiluted`	$-1.66	USD	3 Qtrs
Net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in usd per share)	`EarningsPerShareDiluted`	$-3.11	USD	3 Qtrs
Net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in usd per share)	`EarningsPerShareDiluted`	$-0.78	USD	1 Quarter
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	99.55M	shares	1 Quarter
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	96.66M	shares	3 Qtrs
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	101.18M	shares	3 Qtrs
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	101.42M	shares	1 Quarter
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	96.66M	shares	3 Qtrs
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	101.18M	shares	3 Qtrs
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	101.42M	shares	1 Quarter
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	99.55M	shares	1 Quarter

Cash Flow Statement 97 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-312.46M	USD	3 Qtrs
Net loss	`ProfitLoss`	$-71.67M	USD	1 Quarter
Net loss	`ProfitLoss`	$-153.24M	USD	3 Qtrs
Net loss	`ProfitLoss`	$-107.53M	USD	1 Quarter
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$16.18M	USD	3 Qtrs
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$11.46M	USD	3 Qtrs
Non-cash operating lease costs	`NonCashOperatingLeaseCosts`	$17.78M	USD	3 Qtrs
Non-cash operating lease costs	`NonCashOperatingLeaseCosts`	$3.35M	USD	3 Qtrs
Charge of in-process research and development costs with no alternative future use	`ChargeOfInProcessResearchAndDevelopment`	$8.50M	USD	3 Qtrs
Charge of in-process research and development costs with no alternative future use	`ChargeOfInProcessResearchAndDevelopment`	-	USD	3 Qtrs
Re-valuation of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$-120.00K	USD	3 Qtrs
Re-valuation of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$1.84M	USD	3 Qtrs
Non-cash stock-based compensation	`ShareBasedCompensation`	$124.59M	USD	3 Qtrs
Non-cash stock-based compensation	`ShareBasedCompensation`	$87.35M	USD	3 Qtrs
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$1.92M	USD	3 Qtrs
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	-	USD	3 Qtrs
Amortization of premium (discount) on marketable securities	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$-1.64M	USD	3 Qtrs
Amortization of premium (discount) on marketable securities	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$-9.55M	USD	3 Qtrs
Credit loss adjustment and others	`OtherNoncashIncomeExpense`	$-8.00K	USD	3 Qtrs
Credit loss adjustment and others	`OtherNoncashIncomeExpense`	$-8.06M	USD	3 Qtrs
Accounts receivable, net	`IncreaseDecreaseInAccountsReceivable`	$-11.58M	USD	3 Qtrs
Accounts receivable, net	`IncreaseDecreaseInAccountsReceivable`	$7.45M	USD	3 Qtrs
Inventory	`IncreaseDecreaseInInventories`	$2.02M	USD	3 Qtrs
Inventory	`IncreaseDecreaseInInventories`	$12.55M	USD	3 Qtrs
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-491.00K	USD	3 Qtrs
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$5.76M	USD	3 Qtrs
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$3.23M	USD	3 Qtrs
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$7.57M	USD	3 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$846.00K	USD	3 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$6.94M	USD	3 Qtrs
Accrued compensation	`IncreaseDecreaseInEmployeeRelatedLiabilities`	$10.56M	USD	3 Qtrs
Accrued compensation	`IncreaseDecreaseInEmployeeRelatedLiabilities`	$5.48M	USD	3 Qtrs
Accrued expenses and other liabilities	`IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities`	$10.48M	USD	3 Qtrs
Accrued expenses and other liabilities	`IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities`	$-1.51M	USD	3 Qtrs
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiabilities`	$258.00K	USD	3 Qtrs
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiabilities`	$-3.52M	USD	3 Qtrs
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$-1.23M	USD	3 Qtrs
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$-4.94M	USD	3 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-132.03M	USD	3 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-44.70M	USD	3 Qtrs
Purchases of marketable securities	`PaymentsToAcquireMarketableSecurities`	$580.17M	USD	3 Qtrs
Purchases of marketable securities	`PaymentsToAcquireMarketableSecurities`	$334.08M	USD	3 Qtrs
Maturity of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$627.11M	USD	3 Qtrs
Maturity of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$307.55M	USD	3 Qtrs
Purchase of non-marketable equity and other related investments	`PaymentsToAcquireEquitySecuritiesFvNi`	-	USD	3 Qtrs
Purchase of non-marketable equity and other related investments	`PaymentsToAcquireEquitySecuritiesFvNi`	$39.08M	USD	3 Qtrs
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$28.89M	USD	3 Qtrs
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$50.41M	USD	3 Qtrs
Purchase of intangible assets and capitalized license obligations	`PaymentsToAcquireIntangibleAssets`	-	USD	3 Qtrs
Purchase of intangible assets and capitalized license obligations	`PaymentsToAcquireIntangibleAssets`	$17.89M	USD	3 Qtrs
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$203.54M	USD	3 Qtrs
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-319.40M	USD	3 Qtrs
Payments made on finance lease obligations	`FinanceLeasePrincipalPayments`	$125.00K	USD	3 Qtrs
Payments made on finance lease obligations	`FinanceLeasePrincipalPayments`	$129.00K	USD	3 Qtrs
Proceeds from issuance of common stock upon exercise of stock options	`ProceedsFromStockOptionsExercised`	$7.40M	USD	3 Qtrs
Proceeds from issuance of common stock upon exercise of stock options	`ProceedsFromStockOptionsExercised`	$7.07M	USD	3 Qtrs
Proceeds from issuances of common stock under employee stock purchase plan	`ProceedsFromStockPlans`	$5.40M	USD	3 Qtrs
Proceeds from issuances of common stock under employee stock purchase plan	`ProceedsFromStockPlans`	$3.96M	USD	3 Qtrs
Taxes paid related to net share settlement of restricted stock units	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$82.16M	USD	3 Qtrs
Taxes paid related to net share settlement of restricted stock units	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$2.25M	USD	3 Qtrs
Proceeds from public offering, net of underwriting discounts and commissions	`ProceedsFromIssuanceOfCommonStock`	$355.73M	USD	3 Qtrs
Proceeds from public offering, net of underwriting discounts and commissions	`ProceedsFromIssuanceOfCommonStock`	-	USD	3 Qtrs
Payment of offering costs related to public offering	`PaymentsOfStockIssuanceCosts`	$1.13M	USD	3 Qtrs
Payment of offering costs related to public offering	`PaymentsOfStockIssuanceCosts`	-	USD	3 Qtrs
Payment of offering costs related to borrowings on convertible senior notes	`PaymentsOfDebtIssuanceCosts`	-	USD	3 Qtrs
Payment of offering costs related to borrowings on convertible senior notes	`PaymentsOfDebtIssuanceCosts`	$784.00K	USD	3 Qtrs
Net cash (used in) provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$363.58M	USD	3 Qtrs
Net cash (used in) provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-70.60M	USD	3 Qtrs
Net effect of foreign exchange rate changes on cash, cash equivalents and restricted cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$239.00K	USD	3 Qtrs
Net effect of foreign exchange rate changes on cash, cash equivalents and restricted cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-1.19M	USD	3 Qtrs
Net increase in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-283.00K	USD	3 Qtrs
Net increase in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-284.00K	USD	3 Qtrs
Cash and cash equivalentsBeginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$143.23M	USD	Point-in-time
Cash and cash equivalentsBeginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$832.98M	USD	Point-in-time
Cash and cash equivalentsBeginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$832.69M	USD	Point-in-time
Cash and cash equivalentsBeginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$142.94M	USD	Point-in-time
Cash, cash equivalents and restricted cashEnd of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$143.23M	USD	Point-in-time
Cash, cash equivalents and restricted cashEnd of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$832.98M	USD	Point-in-time
Cash, cash equivalents and restricted cashEnd of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$832.69M	USD	Point-in-time
Cash, cash equivalents and restricted cashEnd of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$142.94M	USD	Point-in-time
Operating lease liabilities arising from obtaining right-of-use assets	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	$171.07M	USD	3 Qtrs
Operating lease liabilities arising from obtaining right-of-use assets	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	$10.46M	USD	3 Qtrs
Purchases of property and equipment included in accounts payable and accrued expenses	`CapitalExpendituresIncurredButNotYetPaid`	$9.59M	USD	3 Qtrs
Purchases of property and equipment included in accounts payable and accrued expenses	`CapitalExpendituresIncurredButNotYetPaid`	$4.30M	USD	3 Qtrs
Issuance costs related to purchase of non-marketable equity and other related investments included in accounts payable and accrued expenses	`EquitySecuritiesFVNIIncurredButNotYetPaid`	$346.00K	USD	3 Qtrs
Issuance costs related to purchase of non-marketable equity and other related investments included in accounts payable and accrued expenses	`EquitySecuritiesFVNIIncurredButNotYetPaid`	-	USD	3 Qtrs
Property and equipment acquired under finance leases	`PropertyPlantAndEquipmentAcquiredUnderFinanceLeases`	$238.00K	USD	3 Qtrs
Property and equipment acquired under finance leases	`PropertyPlantAndEquipmentAcquiredUnderFinanceLeases`	$47.00K	USD	3 Qtrs
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$142.94M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$832.37M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$832.98M	USD	Point-in-time
Restricted cash included in other assets, net	`RestrictedCashNoncurrent`	$323.00K	USD	Point-in-time
Restricted cash included in other assets, net	`RestrictedCashNoncurrent`	-	USD	Point-in-time
Total cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$143.23M	USD	Point-in-time
Total cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$832.98M	USD	Point-in-time
Total cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$832.69M	USD	Point-in-time
Total cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$142.94M	USD	Point-in-time

Stockholders Equity 46 line items

Line Item	Tag	Value	Unit	Period
Adjustments to additional paid in capital, stock issued, issuance costs	`AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts`	$1.13M	USD	3 Qtrs
Adjustment of redeemable noncontrolling interest	`ReclassificationsOfTemporaryToPermanentEquity`	$-2.30M	USD	3 Qtrs
Adjustment of redeemable noncontrolling interest	`ReclassificationsOfTemporaryToPermanentEquity`	$-6.80M	USD	3 Qtrs
Adjustment of redeemable noncontrolling interest	`ReclassificationsOfTemporaryToPermanentEquity`	$-6.00M	USD	1 Quarter
Beginning balance	`StockholdersEquity`	$1.30B	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$1.11B	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$798.39M	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$1.09B	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$788.07M	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$709.42M	USD	Point-in-time
Issuance of common stock in public offering, net of offering costs (in shares)	`StockIssuedDuringPeriodSharesNewIssues`	4.31M	shares	Point-in-time
Issuance of common stock in public offering, net of offering costs	`StockIssuedDuringPeriodValueNewIssues`	$354.60M	USD	Point-in-time
Issuance of common stock in public offering, net of offering costs	`StockIssuedDuringPeriodValueNewIssues`	$354.60M	USD	3 Qtrs
Issuance of common stock upon exercise of stock options (in shares)	`StockIssuedDuringPeriodSharesStockOptionsExercised`	629,246.00	shares	3 Qtrs
Issuance of common stock upon exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$3.85M	USD	1 Quarter
Issuance of common stock upon exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$1.68M	USD	1 Quarter
Issuance of common stock upon exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$7.40M	USD	3 Qtrs
Issuance of common stock upon exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$7.07M	USD	3 Qtrs
Vesting of common stock exercised early	`StockIssuedDuringPeriodValueStockOptionsExercisedEarly`	$39.00K	USD	3 Qtrs
Vesting of common stock exercised early	`StockIssuedDuringPeriodValueStockOptionsExercisedEarly`	$13.00K	USD	1 Quarter
Vesting of common stock exercised early	`StockIssuedDuringPeriodValueStockOptionsExercisedEarly`	$13.00K	USD	1 Quarter
Vesting of common stock exercised early	`StockIssuedDuringPeriodValueStockOptionsExercisedEarly`	$39.00K	USD	3 Qtrs
Common stock issued under employee stock purchase plan	`StockIssuedDuringPeriodValueEmployeeStockPurchasePlan`	$5.40M	USD	3 Qtrs
Common stock issued under employee stock purchase plan	`StockIssuedDuringPeriodValueEmployeeStockPurchasePlan`	$3.96M	USD	3 Qtrs
Taxes paid related to net share settlement of restricted stock units	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$2.25M	USD	3 Qtrs
Taxes paid related to net share settlement of restricted stock units	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$7.20M	USD	1 Quarter
Taxes paid related to net share settlement of restricted stock units	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$82.16M	USD	3 Qtrs
Taxes paid related to net share settlement of restricted stock units	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$2.25M	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$35.02M	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$124.59M	USD	3 Qtrs
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$55.20M	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$87.35M	USD	3 Qtrs
Other comprehensive gain (loss), net of tax impact	`OtherComprehensiveIncomeLossNetOfTax`	$-1.53M	USD	1 Quarter
Other comprehensive gain (loss), net of tax impact	`OtherComprehensiveIncomeLossNetOfTax`	$2.75M	USD	3 Qtrs
Other comprehensive gain (loss), net of tax impact	`OtherComprehensiveIncomeLossNetOfTax`	$-626.00K	USD	1 Quarter
Other comprehensive gain (loss), net of tax impact	`OtherComprehensiveIncomeLossNetOfTax`	$-3.29M	USD	3 Qtrs
Net loss	`ProfitLoss`	$-312.46M	USD	3 Qtrs
Net loss	`ProfitLoss`	$-71.67M	USD	1 Quarter
Net loss	`ProfitLoss`	$-153.24M	USD	3 Qtrs
Net loss	`ProfitLoss`	$-107.53M	USD	1 Quarter
Ending balance	`StockholdersEquity`	$1.30B	USD	Point-in-time
Ending balance	`StockholdersEquity`	$1.11B	USD	Point-in-time
Ending balance	`StockholdersEquity`	$798.39M	USD	Point-in-time
Ending balance	`StockholdersEquity`	$1.09B	USD	Point-in-time
Ending balance	`StockholdersEquity`	$788.07M	USD	Point-in-time
Ending balance	`StockholdersEquity`	$709.42M	USD	Point-in-time

Comprehensive Income 28 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-312.46M	USD	3 Qtrs
Net loss	`ProfitLoss`	$-71.67M	USD	1 Quarter
Net loss	`ProfitLoss`	$-153.24M	USD	3 Qtrs
Net loss	`ProfitLoss`	$-107.53M	USD	1 Quarter
Unrealized gain (loss) on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$2.51M	USD	3 Qtrs
Unrealized gain (loss) on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-513.00K	USD	1 Quarter
Unrealized gain (loss) on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-2.10M	USD	3 Qtrs
Unrealized gain (loss) on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-1.72M	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax`	$239.00K	USD	3 Qtrs
Foreign currency translation adjustments	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax`	$191.00K	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax`	$-1.19M	USD	3 Qtrs
Foreign currency translation adjustments	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax`	$-113.00K	USD	1 Quarter
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-1.53M	USD	1 Quarter
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$2.75M	USD	3 Qtrs
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-626.00K	USD	1 Quarter
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-3.29M	USD	3 Qtrs
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-108.15M	USD	1 Quarter
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-315.75M	USD	3 Qtrs
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-73.20M	USD	1 Quarter
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-150.49M	USD	3 Qtrs
Comprehensive income (loss) attributable to redeemable noncontrolling interest	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest`	$2.30M	USD	3 Qtrs
Comprehensive income (loss) attributable to redeemable noncontrolling interest	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest`	$6.80M	USD	3 Qtrs
Comprehensive income (loss) attributable to redeemable noncontrolling interest	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest`	$6.00M	USD	1 Quarter
Comprehensive income (loss) attributable to redeemable noncontrolling interest	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest`	-	USD	1 Quarter
Comprehensive loss attributable to Guardant Health, Inc.	`ComprehensiveIncomeNetOfTax`	$-157.29M	USD	3 Qtrs
Comprehensive loss attributable to Guardant Health, Inc.	`ComprehensiveIncomeNetOfTax`	$-108.15M	USD	1 Quarter
Comprehensive loss attributable to Guardant Health, Inc.	`ComprehensiveIncomeNetOfTax`	$-318.05M	USD	3 Qtrs
Comprehensive loss attributable to Guardant Health, Inc.	`ComprehensiveIncomeNetOfTax`	$-79.20M	USD	1 Quarter

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.